USER FEE REPORTS OVERDUE FROM FDA ARE UNDERGOING "FINAL CLEARANCE," FDA's KESSLER ASSURES SENATE HEARING; PHARMACY COMPOUNDING PROGRAM QUESTIONED
FDA's two delayed reports on the prescription drug user fee program have been prepared by the agency and are wending their way through HHS review, FDA Commissioner Kessler indicated during an FY 1995 budget hearing before the Senate Appropriations/Agriculture Subcommittee on May 10. The two reports are in final clearance "within the Department of Health and Human Services," Kessler testified.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth